After baseline screening, patients were randomly assigned by a computer-generated randomization sequence to intervention or control groups in a 2:1 ratio. Randomization was stratified by clinical center and was done via a centralized system with block sizes of six (four intervention, two control). An independent statistician who had no involvement in the design or analysis of the study generated the randomization sequence. The centralized computer system was password protected and accessed by the principal investigator or study coordinator after the patient gave consent and had met inclusion criteria. The patients' initials and date of birth were entered and then the patient was allocated to intervention or control. Participants and clinicians were not masked to treatment assignment.
Bayesian Design Rationale
The PROTECT AF trial was designed as a collaborative, adaptive design effort between the sponsor and FDA, both to reduce the time needed to evaluate the primary, non-inferiority endpoint. Per the FDA Draft Guidance for the Use of Bayesian Statistics in Medical Device Clinical Trials, "Adaptive designs use accumulating data to decide on how to modify certain aspects of a trial according to a pre-specified plan. They are often used to potentially reduce the size of a trial by stopping the trial early when conditions warrant. Adaptive trial designs can sometimes be easier to implement using Bayesian methods than frequentist methods. By adhering to the Likelihood Principle, a Bayesian approach can offer flexibility in the design and analysis of adaptive trials." Sequential evaluation of the statistical objective allowed for early stopping for futility or non-inferiority if the study data gave clear indications for the decision and limiting patient exposure to an experimental novel therapy. The Bayesian methodology is one particular method of implementing a sequential evaluation.
Differential Attrition
To explain how the potential effects of differential withdrawals on these results, it may be insightful to look at each randomized group, and evaluate some additional analyses to try to mitigate some of the biases. On the one hand, it should not be surprising that there was greater withdrawal of consent in the Control group. After all, patients specifically entered this randomized device vs warfarin trial specifically to avoid taking further warfarin. So if one is then randomized to Control, ie the same therapy they were/would be receiving if not in the trial, it is entirely plausible that some patients might prefer to not remain in the trial because of no perceived benefit, or a desire to pursue alternative treatments (such as a Factor II/Xa inhibitor). But of course, regardless of the reason, the issue of how the missing patients might bias the trial results is a critical issue. Accordingly, we have performed several additional analyses to assess the effect of these missing patients. First, we examined those patients that dropped out as compared to those that remained in the study. Looking at baseline characteristics, such as age, sex, CHADS score, etc, the patients that dropped out were not statistically significantly different than those who remained in the study (Appendix, eTable 3). Second, if we look at the ability of Control patients to adhere to warfarin dose regulation -which tracks with events in multiple studies -the patients who dropped out had a worse TTR prior to dropping out (64%) than those who remained in the study (70%). This indicates that it was the higher risk Control patients that actually dropped out. This suggests that the patients remaining in the study would actually be of lower risk, and therefore less likely to have events -ultimately biasing the study against the Device group. Third, we performed a conservative sensitivity analysis in which ALL Control patients who dropped out are assumed to be low risk, with no event after study withdrawal, and included them in the analysis (Appendix, eTable 4). Even in this scenario, the rate ratio for the primary efficacy analysis would be 0.71 and non-inferiority would still be maintained with a posterior probability > 99.9% (of course, the posterior probability for superiority would then become 86.2%). Finally, we decided to try to obtain vital status data on the missing patients. This was complicated by the fact that no patient identifiers were collected in the trial database. Thus, we manually queried each center to determine if they could provide vital status data on these subjects (based on their centers' institutional policies); this was acquired from 76 of the 192 patients that withdrew early (and included 24 additional deaths). Based on this updated data, the Per-protocol defined at time interval after the requisite 45-day period of warfarin post implantation (Day 0 is designated the day after stopping warfarin).
Terminal therapy defined at time interval when device patient discontinues clopidogrel and remains on aspirin alone. Per-protocol defined at time interval after the requisite 45-day period of warfarin post implantation (Day 0 is designated the day after stopping warfarin).
Terminal therapy defined at time interval when device patient discontinues clopidogrel and remains on aspirin alone. Early defined study exit prior to the final 5-year follow-up visit.
Remaining is defined as those patients still in the study for this analysis. 
